Flagship Pioneering, Inc.

Flagship Pioneering, Inc., founded in 2000, is a life science venture creation and investment firm that conceives, resources and grows first-in-category companies in human health and sustainability. It works at the intersection of life science innovation, company creation and capital investment, originating ventures from scientific questions judged speculative at the outset and developing them through rigorous research into commercial entities. The firm has originated more than 120 scientific ventures and now counts over 40 companies in its ecosystem, employing more than 9,000 people across them, with over 2,500 patents granted worldwide.

Flagship's portfolio spans several technical domains. Moderna, a Flagship venture, developed one of the first widely deployed mRNA COVID-19 vaccines. Other companies include Generate:Biomedicines, which applies computational biology and machine learning to therapeutics; Tessera Therapeutics, working on gene writing and genetic medicine; Seres Therapeutics, in microbiome therapeutics; and Indigo Agriculture, in agricultural science and the microbiome. Aggregate value created across the portfolio exceeds $90 billion.

The firm's stated approach begins with seemingly unreasonable "what-if" questions and proceeds by navigating scientific uncertainty toward transformational outcomes, with a focus on unmet needs in human health and sustainability. Its verticals include life sciences, therapeutics and biotechnology, agriculture and sustainability. Headquartered in Cambridge, Massachusetts, Flagship operates with a global reach reflected in its worldwide patent portfolio.